Ex situ heart perfusion: a novel model for drug validation and translation - Summary - MDSpire

Ex situ heart perfusion: a novel model for drug validation and translation

  • By

  • John Onsy Louca

  • Magnus Althage

  • Nicole Asemota

  • Johannes Bargehr

  • Sai Bhagra

  • Dawn E. Bowles

  • Sarah Hosgood

  • Kiran Khush

  • Simon Messer

  • Marco Öchsner

  • Joao Pedro Nunes

  • Amanda Rodgers

  • Lu Wang

  • Catherine H. Wilson

  • Stephen Large

  • Sanjay Sinha

  • June 18, 2026

  • 0 min

Share

Objective:

To discuss the potential of ex situ heart perfusion (ESHP) for early testing of novel therapeutics in human hearts and its implications for drug discovery.

Approach:
    Key Findings:
    • 90% of drugs entering clinical trials fail, primarily due to lack of efficacy, particularly in cardiovascular medicine.
    • Current drug testing predominantly relies on cell lines and animal models, which have significant limitations.
    • ESHP provides a safe human model for testing therapeutics with minimal risk to patients.
    Interpretation:

    The potential of ESHP remains largely untapped in drug development, and its adoption could streamline the drug discovery process.

    Limitations:
    • The need for prolonged ex situ perfusion times to enable effective testing.
    • Collaboration between industry, academics, and clinicians is essential for the successful widespread adoption of this model.
    Conclusion:

    Widespread adoption of ESHP could enhance the efficiency of drug discovery pipelines by allowing earlier abandonment of ineffective therapeutics, contingent on collaboration and institutional changes.

Original Source(s)

Related Content